ACT-FASTER, a Prospective Cohort Study Exploring Treatment Patterns with Fulvestrant and Exemestane in Postmenopausal Patients with Advanced Hormone Receptor-Positive Breast Cancer under Real-Life Conditions in Germany.
Advanced breast cancer
Endocrine therapy
Exemestane
Fulvestrant
Journal
Breast care (Basel, Switzerland)
ISSN: 1661-3791
Titre abrégé: Breast Care (Basel)
Pays: Switzerland
ID NLM: 101254060
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
15
1
2020
pubmed:
15
1
2020
medline:
15
1
2020
Statut:
ppublish
Résumé
Endocrine therapy is recommended for the treatment of postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC). ACT-FASTER was a German prospective non-interventional cohort study in postmenopausal women with HR+ ABC receiving fulvestrant 500 mg as first line (1 L), second line (2 L) or third line (3 L), or exemestane (any line) in the real-world palliative setting. Primary study objectives included the effectiveness of fulvestrant according to line of palliative treatment measured by time to progression (TTP), and real-life data on the epidemiology and management of these patients. Of 498 evaluable patients (mean age 67.5 years), 99% were estrogen receptor-positive. On study, 86.7% of patients received fulvestrant 500 mg and 13.3% exemestane. Median TTP was 9.7 months in patients receiving fulvestrant 1 L; 6.8 months for 2 L; and 6.7 months for 3 L. The comparison between fulvestrant 1 L palliative treatment and 2 L or 3 L showed that early initiation of treatment prolonged TTP (hazard ratio 1.26; 95% confidence interval 1.08-1.48). Treatments were well tolerated. Fulvestrant 500 mg was administered successfully to patients under daily practice conditions, and both medications were well tolerated. TTP was longest in patients treated with fulvestrant 500 mg 1 L compared with 2 L and 3 L in the palliative care setting.
Sections du résumé
BACKGROUND
BACKGROUND
Endocrine therapy is recommended for the treatment of postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC).
METHODS
METHODS
ACT-FASTER was a German prospective non-interventional cohort study in postmenopausal women with HR+ ABC receiving fulvestrant 500 mg as first line (1 L), second line (2 L) or third line (3 L), or exemestane (any line) in the real-world palliative setting. Primary study objectives included the effectiveness of fulvestrant according to line of palliative treatment measured by time to progression (TTP), and real-life data on the epidemiology and management of these patients.
RESULTS
RESULTS
Of 498 evaluable patients (mean age 67.5 years), 99% were estrogen receptor-positive. On study, 86.7% of patients received fulvestrant 500 mg and 13.3% exemestane. Median TTP was 9.7 months in patients receiving fulvestrant 1 L; 6.8 months for 2 L; and 6.7 months for 3 L. The comparison between fulvestrant 1 L palliative treatment and 2 L or 3 L showed that early initiation of treatment prolonged TTP (hazard ratio 1.26; 95% confidence interval 1.08-1.48). Treatments were well tolerated.
CONCLUSION
CONCLUSIONS
Fulvestrant 500 mg was administered successfully to patients under daily practice conditions, and both medications were well tolerated. TTP was longest in patients treated with fulvestrant 500 mg 1 L compared with 2 L and 3 L in the palliative care setting.
Identifiants
pubmed: 31933587
doi: 10.1159/000493882
pii: brc-0014-0401
pmc: PMC6940445
doi:
Types de publication
Journal Article
Langues
eng
Pagination
401-408Informations de copyright
Copyright © 2019 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
PK, HO, HT received remuneration from AstraZeneca. LM is an employee of AstraZeneca. HO and DB have undertaken consultant/advisory roles, and HO has received funding from and owns stocks in AstraZeneca. NM and KP declare that they have no competing interests.
Références
Breast. 2001 Jun;10(3):198-208
pubmed: 14965585
Int J Womens Health. 2015 May 27;7:551-63
pubmed: 26064072
Cancer. 2012 Jan 1;118(1):241-7
pubmed: 21717449
J Clin Oncol. 2008 Apr 1;26(10):1664-70
pubmed: 18316794
Breast Cancer Res Treat. 2013 Jun;139(2):441-51
pubmed: 23715630
J Clin Oncol. 2008 Oct 20;26(30):4883-90
pubmed: 18794551
Breast Cancer Res Treat. 2012 May;133(1):237-46
pubmed: 22286314
J Clin Oncol. 2000 Apr;18(7):1399-411
pubmed: 10735887
BMC Med. 2015 Mar 05;13:46
pubmed: 25857348
N Engl J Med. 2012 Aug 2;367(5):435-44
pubmed: 22853014
Lancet Oncol. 2013 Sep;14(10):989-98
pubmed: 23902874
J Clin Oncol. 2010 Oct 20;28(30):4594-600
pubmed: 20855825
J Clin Oncol. 2009 Sep 20;27(27):4530-5
pubmed: 19704066
J Clin Oncol. 2012 Jun 1;30(16):1919-25
pubmed: 22370325